RVLP - RVL Pharmaceuticals plc Stock Price, Fair Value and News

0USD0Delayed

RVLP Stock Price

View Fullscreen

RVLP RSI Chart

RVLP Valuation

EV/EBITDA

-0.51

RVLP Price/Sales (Trailing)

RVLP Profitability

EBT Margin

-185.66%

Return on Equity

-418.14%

Return on Assets

-79.93%

RVLP Fundamentals

RVLP Revenue

Revenue (TTM)

36.9M

RVLP Earnings

Earnings (TTM)

-68.3M

Breaking Down RVLP Revenue

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-100%

How does RVLP drawdown profile look like?

RVLP Financial Health

Current Ratio

0.38

Debt/Equity

3.25

Debt/Cashflow

-0.84

RVLP Investor Care

Shares Dilution (1Y)

0.39%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	37.1M	36.9M	0	0
2022	38.0M	34.9M	42.8M	49.7M
2021	25.2M	22.6M	20.1M	17.5M
2020	158.6M	115.0M	71.4M	27.8M
2019	261.0M	246.7M	245.8M	202.2M
2018	250.2M	254.7M	259.2M	263.7M
2017	0	0	0	245.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of RVL Pharmaceuticals plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 20, 2023	harsaul foundation	sold	-148,478	0.0312	-4,758,900	-
Oct 20, 2023	altchem ltd	sold	-148,478	0.0312	-4,758,900	-
Oct 19, 2023	harsaul foundation	sold	-431,669	0.0461	-9,363,760	-
Oct 19, 2023	altchem ltd	sold	-431,669	0.0461	-9,363,760	-
Oct 18, 2023	harsaul foundation	sold	-221,031	0.0646	-3,421,540	-
Oct 18, 2023	altchem ltd	sold	-221,031	0.0646	-3,421,540	-
Aug 15, 2023	avista healthcare partners gp, ltd.	sold	-	-	-23,730,900	-
Aug 10, 2023	lask alisa	sold (taxes)	-5,880	0.49	-12,000	-
Jul 05, 2023	debiasi michael j.	acquired	-	-	40,000	-
Jul 05, 2023	lask alisa	acquired	-	-	40,000	-

Which funds bought or sold RVLP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	sold off	-100	-71.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-21,334	-	-%
Feb 15, 2024	TITLEIST ASSET MANAGEMENT, LLC	sold off	-100	-8,672	-	-%
Feb 14, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-4,205	-	-%
Feb 14, 2024	Blackstone Inc.	sold off	-100	-56,904	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	CANTOR FITZGERALD, L. P.	sold off	-100	-1,921	-	-%
Feb 14, 2024	BNP PARIBAS ARBITRAGE, SNC	sold off	-100	-	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-23,606	-	-%

Are Funds Buying or Selling RVLP?

Are funds buying RVLP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVLP

No. of Funds

Unveiling RVL Pharmaceuticals plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 28, 2023	athyrium opportunities iv acquisition 2 lp	7.3%	8,148,832	SC 13D/A
Nov 01, 2023	altchem ltd	1.1%	1,182,243	SC 13D/A
Oct 13, 2023	athyrium opportunities iv acquisition 2 lp	7.3%	8,148,832	SC 13D/A
Sep 05, 2023	athyrium opportunities iv acquisition 2 lp	7.3%	8,148,832	SC 13D
Aug 17, 2023	avista healthcare partners gp, ltd.	-	0	SC 13D/A
Jan 30, 2023	avista healthcare partners gp, ltd.	23.9%	23,730,864	SC 13D/A

Recent SEC filings of RVL Pharmaceuticals plc

View All Filings

Date Filed	Form Type	Document
Feb 13, 2024	8-K	Current Report

Peers (Alternatives to RVL Pharmaceuticals plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

RVL Pharmaceuticals plc News

Latest updates

RVL Pharmaceuticals plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-6.5%	8,258,000	8,832,000	9,807,000	10,022,000	8,448,000	21,444,000	2,860,000	2,196,000	11,510,000	6,322,500	1,135,000	25,751,000	37,200,000	48,649,000	57,055,000	65,461,000	57,532,000	57,126,000	65,696,402	66,344,845	71,858,902
Gross Profit	-3.4%	6,312,000	6,533,000	7,247,000	7,497,000	6,221,000	19,300,000	1,777,000	1,049,000	10,801,000	256,000	-14,246,500	24,566,000	-27,000	28,059,000	-92,880,000	38,149,000	24,888,000	27,923,000	28,109,750	32,988,637	37,286,175
Operating Expenses	68.4%	28,333,000	16,824,000	31,795,000	21,419,000	21,345,000	24,696,000	25,378,000	26,217,000	30,979,000	19,156,000	49,828,500	23,139,000	17,290,000	26,864,000	-223,369,000	161,149,000	156,637,000	31,420,000	134,638,892	35,589,629	25,542,722
S&GA Expenses	-14.3%	13,886,000	16,198,000	17,601,000	20,375,000	20,169,000	23,834,000	24,158,500	24,841,000	21,047,000	16,952,000	17,373,500	21,360,000	14,337,000	21,176,000	12,809,500	24,751,000	25,511,000	21,656,000	22,953,415	17,451,680	16,675,943
R&D Expenses	-12.6%	547,000	626,000	884,000	1,044,000	1,176,000	862,000	1,219,500	1,376,000	2,052,000	2,204,000	3,545,000	1,779,000	2,953,000	5,688,000	-29,500	8,285,000	5,360,000	9,764,000	14,587,982	11,964,949	7,970,516
EBITDA Margin	-25.0%	-1.81	-1.45	-0.97	-1.14	-1.74	-1.77	-4.04	-5.57	-3.05	-2.94	-2.06	1.96	0.12	-	-	-	-	-	-	-	-
Interest Expenses	-50.0%	13,000	26,000	15,000	1,132,000	978,000	985,000	1,286,000	735,000	494,000	521,000	-872,000	1,071,000	1,239,000	4,064,000	-7,542,000	4,504,000	4,552,000	4,501,000	5,394,272	5,311,330	5,241,360
Income Taxes	-	-	-	-	-	-	85,000	1,823,000	324,000	94,000	258,000	5,294,000	-1,308,000	-1,150,000	1,000,000	586,000	-14,623,000	-11,447,000	-754,000	-6,084,822	-3,872,001	1,994,272
Earnings Before Taxes	-107.7%	-24,002,000	-11,554,000	-18,604,000	-14,383,000	-11,829,000	-6,896,000	-20,318,500	-26,023,000	-21,874,000	-13,776,000	-63,444,000	407,000	-18,686,000	-2,123,000	138,315,000	-127,327,000	-136,316,000	-7,441,000	-113,090,581	-7,478,257	7,707,501
EBT Margin	-22.2%	-1.86	-1.52	-1.04	-1.25	-1.86	-1.98	-4.68	-6.24	-4.36	-3.79	-3.02	1.65	-0.09	-	-	-	-	-	-	-	-
Net Income	-105.7%	-23,889,000	-11,612,000	-18,319,000	-14,446,000	-12,106,000	-6,821,000	-19,722,000	-17,859,000	-17,727,000	-9,612,000	-54,874,000	-8,633,000	-12,999,000	-3,083,000	-26,641,000	-112,704,000	-124,869,000	-6,687,000	-102,120,000	-3,606,256	5,713,229
Net Income Margin	-21.5%	-1.85	-1.52	-1.04	-1.24	-1.62	-1.63	-3.71	-4.99	-4.01	-3.42	-2.87	-0.72	-1.35	-	-	-	-	-	-	-	-
Free Cashflow	-84.3%	-13,128,000	-7,122,000	-17,123,000	-10,102,000	1,976,000	-13,303,000	-24,520,000	-16,228,000	-3,826,000	-11,908,000	-8,959,000	8,919,000	15,723,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2017Q4
Assets	-23.1%	85.00	111	129	155	125	144	145	110	335	355	371	427	463	475	463	494	644	776	796	895	920
Current Assets	-32.9%	26.00	38.00	57.00	71.00	40.00	59.00	59.00	23.00	249	161	173	176	187	190	173	167	174	164	172	149	115
Cash Equivalents	-41.3%	19.00	33.00	45.00	60.00	27.00	26.00	40.00	8.00	100	109	114	126	140	126	96.00	98.00	64.00	63.00	71.00	32.00	35.00
Inventory	536.6%	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	17.00	2.00	22.00	20.00	21.00	0.00	27.00	28.00	28.00	24.00	26.00	17.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30.00	30.00	30.00	31.00	31.00	31.00	31.00	31.00
Goodwill	0%	56.00	56.00	56.00	56.00	56.00	56.00	56.00	56.00	56.00	101	56.00	101	101	101	56.00	101	101	101	56.00	187	187
Liabilities	-2.9%	69.00	71.00	77.00	87.00	66.00	75.00	68.00	55.00	267	270	277	277	332	331	349	352	389	398	412	464	486
Current Liabilities	316.8%	68.00	16.00	20.00	21.00	19.00	21.00	20.00	54.00	266	49.00	56.00	55.00	59.00	58.00	76.00	79.00	98.00	96.00	114	116	125
Long Term Debt	-100.0%	-	53.00	56.00	56.00	43.00	45.00	44.00	-	-	220	220	219	269	268	268	268	267	267	267	310	314
LT Debt, Current	1291.5%	58.00	4.00	1.00	-	1.00	2.00	2.00	30.00	215	-	-	-	-	-	-	0.00	1.00	1.00	2.00	6.00	7.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	220	220	219	269	268	268	268	267	267	267	310	314
Shareholder's Equity	-59.2%	16.00	40.00	51.00	69.00	59.00	69.00	77.00	55.00	68.00	85.00	94.00	151	131	144	115	142	255	378	384	-	-
Retained Earnings	-4.1%	-604	-580	-569	-550	-536	-524	-517	-497	-479	-462	-452	-397	-389	-376	-373	-346	-233	-108	-102	-	-
Additional Paid-In Capital	0.0%	620	620	619	618	594	593	592	554	550	549	548	550	522	521	489	490	492	491	487	-	-
Shares Outstanding	0.0%	99.00	99.00	99.00	99.00	84.00	83.00	83.00	63.00	63.00	63.00	63.00	60.00	59.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	45.00	-	-	-	62.00	-	-	-	79.00	-	-	-	30.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-107.7%	-12,082	-5,818	-16,423	-10,077	1,976	-13,276	-24,395	-15,937	-2,914	-11,486	-8,252	9,541	16,365	-64.00	675	37,051	1,968	-6,127	30,384	7,228	-7,155
Share Based Compensation	-53.5%	232	499	894	758	1,209	1,209	1,002	4,183	1,232	1,177	1,089	2,073	656	1,107	1,101	1,335	1,327	1,169	-	-	-
Cashflow From Investing	21.7%	-959	-1,225	-172	231	57.00	10.00	-75.00	110,601	-954	6,881	-712	-692	-734	-946	-956	-973	-1,456	-635	-1,145	-806	-744
Cashflow From Financing	90.5%	-460	-4,860	1,396	42,205	-981	-837	56,562	-186,097	-5,559	-236	-3,076	-23,132	-1,085	30,975	-1,879	-1,965	163	-1,010	9,337	-2,363	-1,294
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	3,266	3,749	919	167	-	1,338	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RVLP Income Statement

2023-06-30

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total revenues	$ 8,258	$ 8,448	$ 17,090	$ 29,892
Cost of goods sold	1,946	2,227	4,245	4,371
Gross profit	6,312	6,221	12,845	25,521
Selling, general and administrative expenses	13,886	20,169	30,084	44,003
Research and development expenses	547	1,176	1,173	2,038
Impairment of intangible assets	13,900		13,900
Total operating expenses	28,333	21,345	45,157	46,041
Operating loss	(22,021)	(15,124)	(32,312)	(20,520)
Interest expense and amortization of debt discount	13	978	39	1,963
Change in fair value of debt and interest expense	3,144	(740)	10,493	304
Change in fair value of warrants	(805)	(3,455)	(1,482)	1,053
Other non-operating income, net	(371)	(78)	(5,806)	(5,115)
Total other non-operating expense (income)	1,981	(3,295)	3,244	(1,795)
Loss before income taxes	(24,002)	(11,829)	(35,556)	(18,725)
Income tax (benefit) expense	(113)	277	(55)	202
Net loss	(23,889)	(12,106)	(35,501)	(18,927)
Change in fair value of debt due to change in credit risk, net of tax				(1,700)
Comprehensive loss	$ (23,889)	$ (12,106)	$ (35,501)	$ (20,627)
Loss per ordinary share:
Loss per ordinary share, basic (in dollars per share)	$ (0.24)	$ (0.14)	$ (0.36)	$ (0.23)
Loss per ordinary share, diluted ( in dollars per share)	$ (0.24)	$ (0.14)	$ (0.36)	$ (0.23)
Weighted average ordinary shares outstanding:
Weighted average ordinary shares outstanding, basic (in shares)	99,370,291	83,580,906	99,345,933	83,535,655
Weighted average ordinary shares outstanding, diluted (in shares)	99,370,291	83,580,906	99,345,933	83,535,655
Net product sales
Total revenues	$ 8,258	$ 8,448	$ 17,090	$ 14,392
Royalty and licensing revenue
Total revenues				$ 15,500

RVLP Balance Sheet

2023-06-30

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,159	$ 44,543
Accounts receivable and other receivables	1,932	3,031
Inventories, net	1,356	784
Prepaid expenses and other current assets	3,305	8,617
Total current assets	25,752	56,975
Property, plant and equipment, net	3,440	1,276
Operating lease assets	365	512
Indefinite-lived intangible assets		13,900
Goodwill	55,847	55,847
Total assets	85,404	128,510
Current liabilities:
Trade accounts payable	2,530	2,407
Accrued liabilities	7,857	15,395
Current portion of debt ($6,682 measured at fair value and representing $7,067 of aggregate unpaid principal at June 30, 2023)	57,748	1,432
Current portion of obligations under finance leases	10	10
Current portion of lease liability	197	435
Income taxes payable - current portion	50	44
Total current liabilities	68,392	19,723
Long-term debt (measured at fair value and representing $67,133 and $75,000 of aggregate unpaid principal at June 30, 2023 and December 31, 2022, respectively)		55,500
Warrant liability	469	1,951
Long-term portion of obligations under finance leases	12	18
Long-term portion of lease liability	180	94
Income taxes payable - long term portion		70
Deferred taxes	25	61
Total liabilities	69,078	77,417
Commitments and contingencies (see Note 11)
Shareholders' equity:
Ordinary shares ($0.01 nominal value, 400,000,000 shares authorized, 99,392,165 and 99,161,375 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively)	994	992
Preferred shares ($0.01 nominal value, 40,000,000 shares authorized, no shares issued and outstanding)	0	0
Euro deferred shares (€1.00 nominal value, 25,000 shares authorized, no shares issued and outstanding)	0	0
Additional paid in capital	620,055	619,323
Accumulated deficit	(604,723)	(569,222)
Total shareholders' equity	16,326	51,093
Total liabilities and shareholders' equity	$ 85,404	$ 128,510

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

CEO	Mr. Brian A. Markison
WEBSITE	rvlpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	125

RVL Pharmaceuticals plc Frequently Asked Questions

What is the ticker symbol for RVL Pharmaceuticals plc? What does RVLP stand for in stocks?

RVLP is the stock ticker symbol of RVL Pharmaceuticals plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RVL Pharmaceuticals plc (RVLP)?

As of Thu Dec 21 2023, market cap of RVL Pharmaceuticals plc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVLP stock?

You can check RVLP's fair value in chart for subscribers.

What is the fair value of RVLP stock?

You can check RVLP's fair value in chart for subscribers. The fair value of RVL Pharmaceuticals plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RVL Pharmaceuticals plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVLP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RVL Pharmaceuticals plc a good stock to buy?

The fair value guage provides a quick view whether RVLP is over valued or under valued. Whether RVL Pharmaceuticals plc is cheap or expensive depends on the assumptions which impact RVL Pharmaceuticals plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVLP.

What is RVL Pharmaceuticals plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 21 2023, RVLP's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVLP PE ratio will change depending on the future growth rate expectations of investors.